MAJOR DEPRESSIVE DISORDER · White paper
Major Depressive Disorder (MDD) Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About major depressive disorder (mdd) — and why its trials are hard
Major depressive disorder is a common, serious mood disorder and the leading cause of disability worldwide. About 21.0 million U.S. adults (8.3%) experienced a major depressive episode in a given year, more often women (10.3%) than men (6.2%). Diagnosis follows DSM-5 criteria requiring at least two weeks of symptoms. The pharmacologic armamentarium spans older MAOIs and tricyclics, widely used SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram) and SNRIs (venlafaxine, duloxetine, desvenlafaxine), atypical agents such as bupropion and mirtazapine, and newer mechanisms including esketamine and dextromethorphan-bupropion. Pivotal trials assess change from baseline on the HAM-D or MADRS, plus response (>=50% score reduction), remission, and durability. MDD is notorious for a high, variable placebo response and marked disease heterogeneity, driving an alarming rate of failed efficacy endpoints. High-profile failures include ALKS-5461 (buprenorphine/samidorphan), TC-5214, and zuranolone in MDD (though approved for postpartum depression). Enriching for moderate-to-severe, recurrent patients and tightening trial design are central to improving success.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Fluoxetine (Prozac) | 1987 | Major depressive disorder (SSRI) | Multiple pivotal placebo-controlled studies | Improvement in HAM-D score | Established SSRI efficacy vs placebo; landmark first-in-class SSRI |
| Sertraline (Zoloft) | 1991 | Major depressive disorder (SSRI) | Multiple pivotal studies | Improvement in HAM-D score | Significant reduction in depressive symptoms vs placebo |
| Escitalopram (Lexapro) | 2002 | Major depressive disorder (SSRI) | Multiple pivotal studies | Improvement in HAM-D score | Significant symptom improvement vs placebo; widely prescribed SSRI |
| Duloxetine (Cymbalta) | 2004 | Major depressive disorder (SNRI) | Multiple pivotal studies | Improvement in HAM-D score | Significant reduction in depressive symptoms vs placebo |
| Esketamine (Spravato) | 2019 | Treatment-resistant depression (with an oral antidepressant); later MDD with acute suicidality | TRANSFORM / SUSTAIN program | Change from baseline in MADRS | First intranasal NMDA-receptor antagonist approved for TRD; rapid symptom reduction vs placebo |
| Dextromethorphan/bupropion (Auvelity) | 2022 | Major depressive disorder in adults | GEMINI (one pivotal study) | Improvement in MADRS score | Rapid, significant MADRS improvement vs placebo; oral NMDA-modulating combination |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in major depressive disorder (mdd) development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| ALKS-5461 (buprenorphine/samidorphan) — Phase 3 program (Alkermes) | FDA rejection with Complete Response Letter requesting additional substantial evidence of effectiveness | Phase 3 trials failed to show statistically significant improvement in depressive symptoms vs placebo despite promising early data |
| TC-5214 (AstraZeneca/Targacept) — Multiple Phase 3 trials | Failed to demonstrate statistically significant improvement vs placebo; collaboration dissolved | Inability to reproduce promising earlier results at Phase 3 scale; high placebo response |
| Zuranolone (Zurzuvae) — MDD development program (Sage/Biogen) | Approved for postpartum depression but failed to secure an MDD indication | Insufficient efficacy signal in the broader MDD population despite postpartum success |
Choosing the right endpoint
Primary endpoints that matter in major depressive disorder (mdd) trials
- Change from baseline in HAM-D/HDRS — Classic primary efficacy endpoint measuring depression severity over the trial period
- Change from baseline in MADRS — Widely used depression severity scale; primary endpoint for newer agents such as Auvelity and esketamine
- Response rate — Proportion achieving >=50% reduction in depression severity score from baseline
- Remission rate — Proportion reaching a specified low score indicating minimal or no symptoms
- Durability of response/remission — Sustained benefit over time to ensure remission is not short-lived
How iNGENū runs major depressive disorder (mdd) trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Major Depressive Disorder (MDD) clinical trials — FAQs
Why do so many MDD trials fail on efficacy?
How can trial design reduce the placebo problem?
Can a drug be approved for one depression indication but fail another?
Ready to discuss your major depressive disorder (mdd) trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal